Post ISTH & ASH Headlines 2019



Abstracts selected by Dr Rhona Maclean (Sheffield)

Abstract PB505
Effectiveness and Safety of Rivaroxaban Versus Low Molecular- Weight Heparin for Treatment of Cancer- Associated Thromboembolism
Abstract (PDF)


Abstract 421
Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial
Abstract (PDF)


Abstract 362
Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin
Abstract (PDF)


Abstract 1235
Periprocedural Interruption of Anticoagulation in Patients with Cancer-Associated VTE: An Analysis of Thrombotic and Bleeding Outcomes
Abstract (PDF)


Abstract 3798
The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category
Abstract (PDF)


Abstract LBA-1
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)
Abstract (PDF)


Abstract 144
The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)
Abstract (PDF)


Abstract 2510
Venous Thromboembolism in Cancer Patients Receiving Immunotherapy
Abstract (PDF)


Abstract 1230
Long-Term Risk Factors for Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism: A Post-Hoc Analysis of the Reverse Study
Abstract (PDF)